Screener
Aclaris Therapeutics ACRS Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $19,167 | $19,960 |
| Short-term marketable securities | 72,389 | 70,791 |
| Accounts receivable, prepaid expenses and other current assets | 6,209 | 5,565 |
| Total current assets | 97,765 | 96,316 |
| Marketable securities | 79,065 | 60,612 |
| Property and equipment, net | 664 | 761 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's short-term investments?
- Aclaris Therapeutics (ACRS) reported short-term investments of $72.39M in Q2 2026.
- How has Aclaris Therapeutics's short-term investments changed year-over-year?
- Aclaris Therapeutics's short-term investments decreased by 2.7% year-over-year, from $74.4M to $72.39M.
- What is the long-term trend for Aclaris Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's short-term investments has grown at a 17.2% compound annual growth rate (CAGR), from $32.07M to $70.79M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Aclaris Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude